Marshall Wace
HOWL icon

Marshall Wace’s Werewolf Therapeutics HOWL Stock Holding History

Marshall Wace’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-103,785
Closed -$113K – 3091
2025
Q2 		$113K Buy
+103,785
New +$107K ﹤0.01% 2530
2024
Q3 		– Sell
-134,184
Closed -$327K – 2693
2024
Q2 		$327K Buy
134,184
+107,900
+411% +$518K ﹤0.01% 2116
2024
Q1 		$170K Buy
+26,284
New +$153K ﹤0.01% 2259
2023
Q2 		– Sell
-120,936
Closed -$314K – 2659
2023
Q1 		$314K Buy
+120,936
New +$360K ﹤0.01% 2282

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's HOWL Position: Q3 2025 in Review

Marshall Wace sold out of Werewolf Therapeutics (HOWL) in Q3 2025, closing a stake of 103,785 shares — an estimated $113K sold.

Marshall Wace first reported a position in HOWL in Q1 2023 and held it in 4 quarters. The position peaked at $327K in Q2 2024. 62 funds tracked by Wall St. Rank hold HOWL as of Q3 2025.

  • Marshall Wace reported no remaining Werewolf Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Marshall Wace sold 103,785 Werewolf Therapeutics shares in Q3 2025, an estimated $113K.
  • Marshall Wace first reported a position in Werewolf Therapeutics in Q1 2023 and held it in 4 quarters.
  • Marshall Wace's Werewolf Therapeutics position peaked at $327K in Q2 2024.
  • 62 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.